Yu et al. also confirmed the efficacy of SAS for inducing ferroptosis in breast cancer cells by inhibiting expression of GPX4 and xCT, and upregulating the expression of transferrin receptor (TFRC) and divalent metal transporter 1 (DMT1), especially in cells with low oestrogen receptor (ER) expression [80]. Here, TFRC is linked to breast cancer.